Literature DB >> 18849910

The medical treatment of obsessive-compulsive disorder and anxiety.

Borwin Bandelow1.   

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are first-line pharmacotherapy treatments for obsessive-compulsive disorder (OCD). Clomipramine is effective in OCD but associated with more adverse events. Typically, higher doses of antidepressants are required for OCD. Up to 50% of patients do not respond to initial treatment of OCD. Treatment options for nonresponders include augmentation of antidepressants with atypical antipsychotics, among other strategies. First-line treatments for anxiety disorders include SSRIs, serotonin norepinephrine reuptake inhibitors, and pregabalin. Tricyclic antidepressants are equally effective as SSRIs, but are less well tolerated. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of dependency and tolerance. Other treatment options include irreversible and reversible monoamine oxidase inhibitors, the atypical antipsychotic quetiapine, and other medications. Cognitive-behavioral therapy has been sufficiently investigated in controlled studies of OCD and anxiety disorders and is recommended alone or in combination with the above medications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18849910     DOI: 10.1017/s1092852900026924

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  7 in total

1.  Development and Psychometric Evaluation of the Treatment-Emergent Activation and Suicidality Assessment Profile.

Authors:  Jeannette M Reid; Eric A Storch; Tanya K Murphy; Danielle Bodzin; P Jane Mutch; Heather Lehmkuhl; Michael Aman; Wayne K Goodman
Journal:  Child Youth Care Forum       Date:  2010-02-04

2.  A Microglia Sublineage Protects from Sex-Linked Anxiety Symptoms and Obsessive Compulsion.

Authors:  Dimitri Tränkner; Anne Boulet; Erik Peden; Richard Focht; Donn Van Deren; Mario Capecchi
Journal:  Cell Rep       Date:  2019-10-22       Impact factor: 9.423

3.  Obsessive-compulsive disorder and related disorders: a comprehensive survey.

Authors:  Michele Fornaro; Filippo Gabrielli; Claudio Albano; Stefania Fornaro; Salvatore Rizzato; Chiara Mattei; Paola Solano; Valentina Vinciguerra; Pantaleo Fornaro
Journal:  Ann Gen Psychiatry       Date:  2009-05-18       Impact factor: 3.455

4.  Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.

Authors:  Markus Dold; Martin Aigner; Rupert Lanzenberger; Siegfried Kasper
Journal:  Int J Neuropsychopharmacol       Date:  2015-05-04       Impact factor: 5.176

5.  N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review.

Authors:  Georgina Oliver; Olivia Dean; David Camfield; Scott Blair-West; Chee Ng; Michael Berk; Jerome Sarris
Journal:  Clin Psychopharmacol Neurosci       Date:  2015-04-30       Impact factor: 2.582

6.  Lamotrigine Augmentation Versus Placebo in Serotonin Reuptake Inhibitors-Resistant Obsessive-Compulsive Disorder: A Randomized Controlled Trial.

Authors:  Mohammadrasoul Khalkhali; Setareh Aram; Homa Zarrabi; Moosa Kafie; Abtin Heidarzadeh
Journal:  Iran J Psychiatry       Date:  2016-04

7.  Aligning the many definitions of treatment resistance in anxiety disorders: A systematic review.

Authors:  Wicher A Bokma; Guido A A M Wetzer; Jurriaan B Gehrels; Brenda W J H Penninx; Neeltje M Batelaan; Anton L J M van Balkom
Journal:  Depress Anxiety       Date:  2019-06-23       Impact factor: 6.505

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.